Modern approach to primary cervical cancer screening (literature review)

The problem of morbidity and mortality from cervical cancer is one of the leading in the world medical practice. Many countries began to reconsider the approach to primary screening for cervical cancer after etiological role of human papillomavirus (HPV) in cervical carcinogenesis was determined. Most studies have shown that the identification of HPV DNA has a high prognostic value and can be used both as a co-testing and a primary test. However, the unwillingness of many women to visit a gynecologist due to subjective reasons makes it difficult to implement programs on prevention of cervical cancer. Women associate their unwillingness with the lack of time, discomfort and sickliness, a feeling of shame and confusion, when performing a vaginal examination. To solve this problem, in recent years, self-sampling systems for HPV-testing were devised. Self-sampling systems for HPV-testing are comparable with taking cervical sampler by a doctor; they increase the participation of women in cervical screening. Countries have a reduction in morbidity and mortality from cervical cancer due to the inclusion of the HPV-test in national screening programs. At present, many countries consider the introduction of self-sampling devices for vaginal content for HPV-testing in cervical screening. HPV-self-sampling has the potential to improve participation in screening programs, to reduce socioeconomic barriers to care and to improve the subjective patient experience.

Qvintip, high-risk human papillomavirus, cervical cancer, HPV-test, Qvintip, self-sampling, cervical screening

1. Абрамовских О.С., Долгушина В.Ф., Телешева Л.Ф., Летяева О.И., Антимирова Е.А. Папилломави-русная инфекция урогенитального тракта: эпидемиологические аспекты (обзор) // Гинекология. - 2016. -№ 2. - С. 34-39

2. Адамян Л.В., Артымук Н.В., Ашрафян Л.А., Баранов И.И., Байрамова Г.Р., Белокриницкая Т.Е., Башмакова Н.В., Зароченцева Н.В., Краснопольский В.И., Коломиец Л.А., Короленкова Л.И., Минкина Г.Н., Прилепская В.Н., Полонская Н.Ю., Роговская С.И., Уварова Е.В., Филиппов О.С., Шабалова И.П. Доброкачественные и предраковые заболевания шейки матки с позиции профилактики рака. Клинические рекомендации. - М., 2017. - 54 с

3. Апгар Б.С., Броцман Г.Л., Шпицер М. Клиническая кольпоскопия. Практическое руководство. -М.: Практическая медицина, 2014. - 384 c

4. Артымук Н.В., Марочко К.В. Эффективность выявления вируса папилломы человека при

5. Белокриницкая Т.Е., Фролова Н.И., Туранова О.В., Плетнева В.А., Шемякина К.Н., Самбуева Н.Б., Мальцева Е.Е. Результаты тестирования на вирус папилломы человека при самостоятельном и врачебном заборе материала // Гинекология. - 2017. -№ 1. - С. 56-62

6. Иванов М.К., Дзюбенко В.В., Смирнова С.А., Козлов Д.О., Кандрушин В.Е., Кандрушин Е.В. Распространенность генотипов вируса папилломы человека высокого канцерогенного риска среди пациентов крупной клинико-диагностической лаборатории // Вектор-Бест. - 2016. - № 4. - С. 2-9

7. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2016 году. - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2017. - 236 с

8. Кисина В.И. Инфекции, передаваемые половым путем. Протоколы ведения больных. - М.: НЬЮДИА-МЕД, 2014. - 264 с

9. Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология» (за исключением использования вспомогательных репродуктивных технологий): Приказ Министерства здравоохранения РФ № 572н от 1 ноября 2012 года

10. Об утверждении порядка проведения диспансеризации определённых групп взрослого населения: Приказ Министерства здравоохранения РФ № 36ан от 3 февраля 2015 года

11. Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки. - М.: ГЭОТАР-Медиа, 2014. - 192 с

12. Хрянин А.А., Решетников О.В. Папилломавирусная инфекция: современный взгляд на эпидемиологию, профилактику, лечение // Гинекология. -2013. - № 5. - С. 16-20

13. ервов В.О, Артымук Н.В. Информированность и онкологическая настороженность к раку органов репродуктивной системы у женщин Кемеровской области // Фундаментальная и клиническая медицина. - 2016. - № 1 (1). - С. 64-68

14. Arbyn M., Verdoodt F., Snijders P.J.F., Verhoef V.M.J., Suonio E., Dillner L., Minozzi S., Bellisario C., Banzi R., Zhao F.H., Hillemanns P., Anttila A. (2014). Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol, 15 (2), 172-183.

15. Bosch F.X., Broker T.R., Forman D., Moscicki A.B., Gillison M.L., Doorbar J., Stern P.L., Stanley M., Arbyn M., Poljak M., Cuzick J., Castle P.E., Schiller J.T., Markowitz L.E., Fisher W.A., Canfell K., Denny L.A., Franco E.L., Steben M., Kane M.A., Schiffman M., Meijer C.J., Sankaranarayanan R., Castellsagué X., Kim J.J., Brotons M., Alemany L., Albero G., Diaz M., de Sanjosé S. (2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine, 31 (7), 1-31. D0I:10.1016/j.vaccine.2013.10.003

16. Bruni L., Barrionuevo-Rosas L., Albero G., Serrano B., Mena M., Gômez D., Munoz J., Bosch F.X., de Sanjosé S. (2017). ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases Report. 325 р.

17. Castle P.E., Glass A.G., Rush B.B., Scott D.R., Wentzensen N., Gage J.C., Buckland J., Rydzak G., Lorincz A.T., Wacholder S. (2012). Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol, 30 (25), 3044-3050. DOI: 10.1200/JCO.2011.38.8389

18. World Health Organization. (2014). Comprehensive Cervical Cancer Control. A guide to essential practice, 408 p.

19. Del Mistro A., Frayle H., Ferro A., Fantin G., Altobelli E., Rossi PG. (2016). Efficacy of self-sampling in promoting participation to cervical cancer screening also in subsequent round. Prev Med Rep, 5, 166-68. DOI: 10.1016/j.pmedr.2016.12.017

20. Deleré Y., Schuster M., Vartazarowa E., Hänsel T., Hagemann I., Borchardt S., Perlitz H., Schneider A., Reiter S., Kaufmann A.M. (2011). Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years, J Clin Microbiol, 49 (10), 3519-3522. DOI: 10.1128/JCM.01026-11

21. Doorbar J., Egawa N., Griffin H., Kranjec C., Murakami I. (2015). Human papillomavirus molecular biology and disease association. Rev Med Virol, Suppl 1, 2-23. DOI: 10.1002/rmv.1822

22. Everett T., Bryant A., Griffin M.F., Martin-Hirsch P.P., Forbes C.A., Jepson R.G. (2011). Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev, (5), CD002834. DOI: 10.1002/14651858.CD002834.pub2

23. Gupta S., Palmer C., Bik E.M., Cardenas J.P., Nunez H., Kraal L., Bird S., Bowers J., Smith A., Walton NA, Goddard AD, Almonacid DE, Richman J., Apte ZS. (2017). Self-sampling for HPV testing: increased cervical cancer screening participation and incorporation in international screening programs, Preprints 2017, 2017110199. DOI: 10.20944/ preprints201711.0199.v2

24. Hansen B.T., Hukkelberg S.S., Haldorsen T., Eriksen T., Skare G.B., Nygârd M. (2011). Factors associated with non-attendance, opportunistic attendance and reminded attendance to cervical screening in an organized screening program: a cross-sectional study of 12,058 Norwegian women. BMC Public Health, (11), 264.

25. Jentschke M., Chen K., Arbyn M., Hertel B., Noskowicz M., Soergel P., Hillemanns P. (2016). Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections. J Clin Virol, 82, 46-50. DOI: 10.1016/j.jcv.2016.06.016

26. Jia Y., Li S., Yang R., Zhou H., Xiang Q, Hu T., Zhang Q, Chen Z., Ma D., Feng L. (2013). Knowledge about cervical cancer and barriers of screening program among women in Wufeng County, a high-incidence region of cervical cancer in China. PLos One, 8 (7), e67005

27. Marlow L.A.V., Waller J., Wardle J. (2015). Barriers to cervical cancer screening among ethnic minority women: a qualitative study. J Fam Plann Reprod Health Care, 41 (4), 248-254.

28. Ma’som M., Bhoo-Pathy N., Nasir N.H., Bellinson J., Subramaniam S., Ma Y., Yap S.H., Goh P.P., Gravitt P., Woo Y.L. (2016). Attitudes and factors affecting acceptability of self-administered cervicovaginal sampling for human papillomavirus (HPV) genotyping as an alternative to Pap testing among multiethnic Malaysian women. BMJ Open, 6 (8), e011022. DOI: 10.1136/bmjopen-2015-011022.

29. Nelson E.J., Maynard B.R., Loux T., Fatla J., Gordon R., Arnold L.D. (2017). The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect, 93 (1), 56-61.

30. Rozemeijer K., de Kok IMCM, Naber S.K., van Kemenade F.J., Penning C., van Rosmalen J., van Ballegooijen M. (2015). Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits? Cancer Epidemiol Biomarkers Prev, 24 (5), 773-782.

31. Shaniqua L., Jeanne M.F. (2014). Update on prevention and screening of cervical cancer. World J Clin Oncol, 5 (4), 744-752. DOI: 10.5306/wjco.v5.i4.744

32. Smith M., Lew J.B., Simms K., Canfell K. (2016). Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program. Med J Aust, 204 (5), 1941e-1947e.

33. Toliman P., Badman S.G., Gabuzzi J., Silim S., Forereme L., Kumbia A., Kombuk B., Kombati Z., Allan J., Munnull G., Ryan C., Vallely L.M., Kelly-Hanku A., Wand H., Mola G.D.L., Guy R., Siba P., Kaldor J.M., Tabrizi S.N., Vallely A.J. (2016). Field evaluation of expert HPV point-of-care test for detection of human papillomavirus infection by use of self-collected vaginal and clinician-collected cervical specimens. J Clin Microbiol, 54 (7), 1734-1737. DOI: 10.1128/JCM.00529-16

34. Tranberg M., Bech B.H., Blaakær J., Jensen J.S., Svanholm H., Andersen B. (2016). Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program. BMC Cancer, 16 (1), 835.

35. U.S. Preventive Services Task Force. (2017). Draft recommendation statement: Cervical cancer: Screening. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/draft967.

36. Viviano M., Catarino R., Jeannot E., Boulvain M., Malinverno M.U., Vassilakos P., Petignat P. (2017). Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. Br J Cancer, 116 (11), 1382-1388.

37. Vorsters A., Arbyn M., Baay M., Bosch X., de Sanjosé S., Hanley S., Karafillakis E., Lopalco P.L., Pollock K.G., Yarwood J., Van Damme P. (2017). Overcoming barriers in HPV vaccination and screening programs. Papillomavirus Res, 4, 45-53.

38. Watson M., Benard V., King J., Crawford A., Saraiya M. (2017). National assessment of HPV and Pap tests: Changes in cervical cancer screening, National Health Interview Survey. Prev Med, 100, 243-247. DOI: 10.1016/j.ypmed.2017.05.004

39. World Health Organization. (2013). Comprehensive cervical cancer prevention and control: a healthier future for girls and women, 13 р.

40. Wright T.C., Stoler M.H., Behrens C.M., Sharma A., Zhang G., Wright T.L. (2015). Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol, 136 (2), 189-197. DOI: 10.1016/j.ygyno.2014.11.076